This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Boston Scientific (BSX)

Tipranks - Thu Jul 30, 1:42PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rezolute (RZLT) and Boston Scientific (BSX) with bullish sentiments.

Claim 55% Off TipRanks

Rezolute (RZLT)

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Rezolute today and set a price target of $5.00. The company’s shares closed last Wednesday at $4.73.

According to TipRanks.com, Tsao is a 5-star analyst with an average return of 24.9% and a 56.8% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Neumora Therapeutics, Inc., and Crinetics Pharmaceuticals. ;'>

Currently, the analyst consensus on Rezolute is a Strong Buy with an average price target of $8.43.

See today’s best-performing stocks on TipRanks >>

Boston Scientific (BSX)

Needham analyst Michael Matson maintained a Buy rating on Boston Scientific today and set a price target of $57.00. The company’s shares closed last Wednesday at $46.32.

According to TipRanks.com, Matson is a 4-star analyst with an average return of 5.4% and a 50.2% success rate. Matson covers the Healthcare sector, focusing on stocks such as Insight Molecular Diagnostics, Establishment Labs Holdings, and Merit Medical Systems. ;'>

Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $68.42, implying a 60.3% upside from current levels. In a report issued on July 14, TipRanks – DeepSeek also upgraded the stock to Buy with a $49.00 price target.

Read More on RZLT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.